tiprankstipranks
Advertisement
Advertisement

EYPT Stock Latest News

EyePoint Stockholders Approve Incentive Plan and Board Slate
Company AnnouncementsEyePoint Stockholders Approve Incentive Plan and Board Slate
4d ago
8K
EYPT
Analyst Reiterates Buy on EyePoint, Sees Durability as Key Differentiator with Price Target Maintained at $43
PremiumRatings
Analyst Reiterates Buy on EyePoint, Sees Durability as Key Differentiator with Price Target Maintained at $43
14d ago
EYPT
EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease
PremiumCompany Announcements
EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease
23d ago
EYPT
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
PremiumCompany Announcements
EyePoint Pharma Bets Big on DURAVYU Pivotal Data
1M ago
EYPT
EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
PremiumThe Fly
EyePoint receives positive DSMC recommendation for Duravyu Phase 3 trials
1M ago
EYPT
EyePoint Advances DURAVYU Phase 3 Wet AMD Program
PremiumCompany AnnouncementsEyePoint Advances DURAVYU Phase 3 Wet AMD Program
1M ago
8K
EYPT
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
Premium
Company Announcements
EyePoint Pharma Bets on DURAVYU Amid Mounting Losses
2M ago
EYPT
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
Premium
Ratings
Yi Chen Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target on DURAVYU Late-Stage Progress
2M ago
EYPT
EyePoint reports Q1 EPS (99c), consensus (81c)
PremiumThe Fly
EyePoint reports Q1 EPS (99c), consensus (81c)
2M ago
EYPT
EYPT Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
EYPT Upcoming Earnings Report: What to Expect?
2M ago
EYPT
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
PremiumWeekend Updates
Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
2M ago
AGX
EYPT
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
PremiumCompany Announcements
EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
2M ago
8K
EYPT
EyePoint Sues Ocular Therapeutix Over Alleged Defamation
PremiumCompany AnnouncementsEyePoint Sues Ocular Therapeutix Over Alleged Defamation
3M ago
8K
EYPT
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
Premium
Company Announcements
EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus
3M ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
Premium
The Fly
EyePoint reports inducement grants under NASDAQ listing rule
3M ago
EYPT
EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
PremiumRatings
EyePoint Pharmaceuticals: Strong Clinical Momentum, Favorable Risk‑Reward, and Catalyst‑Rich Path to Duravyu Approval Support Buy Rating
4M ago
EYPT
EyePoint price target raised to $35 from $31 at Citi
PremiumThe Fly
EyePoint price target raised to $35 from $31 at Citi
4M ago
EYPT
EyePoint Pharma Bets Big on DuraVu in Pivotal Push
PremiumCompany Announcements
EyePoint Pharma Bets Big on DuraVu in Pivotal Push
4M ago
EYPT
EyePoint price target raised to $30 from $23 at H.C. Wainwright
PremiumThe Fly
EyePoint price target raised to $30 from $23 at H.C. Wainwright
4M ago
EYPT
EyePoint price target raised to $29 from $27 at Chardan
PremiumThe FlyEyePoint price target raised to $29 from $27 at Chardan
4M ago
EYPT
EyePoint reports Q4 EPS (81c), consensus (75c)
Premium
The Fly
EyePoint reports Q4 EPS (81c), consensus (75c)
4M ago
EYPT
EyePoint expects cash to fund operations into Q4 2027
Premium
The Fly
EyePoint expects cash to fund operations into Q4 2027
4M ago
EYPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >